SCHEMBL16088765

SCHEMBL16088765

Cc1ccc(C(=O)Nc2ccccc2S(=O)(=O)N2CCOCC2)c(F)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.60
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ MAPK1 P28482 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ CREBBP Q92793 2/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ ALB P02768 1/20 0.53
▸ TSHR P16473 3/20 0.51
▸ CNR1 P21554 1/20 0.51
▸ CNR2 P34972 1/20 0.51
▸ TP53 P04637 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ USP2 O75604 1/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16127704 0.89 BCL3 (0.58) POLBSMN1; SMN2MAPK1LMNAHSD17B10
SCHEMBL16088763 0.87 MAPT (0.62) POLBSMN1; SMN2MAPK1LMNAHSD17B10
SCHEMBL16088766 0.81 LMNA (0.68) POLBSMN1; SMN2MAPK1LMNAHSD17B10
SCHEMBL16127703 0.80 ALDH1A1 (0.70) POLBSMN1; SMN2MAPK1LMNAHSD17B10
SCHEMBL16127833 0.78 POLB (0.63) POLBLMNAHSD17B10ALDH1A1TSHR
SCHEMBL16088783 0.78 HTT (0.64) SMN1; SMN2LMNAHSD17B10ALDH1A1ALB
SCHEMBL16088777 0.76 POLB (0.63) POLBMAPK1LMNAHSD17B10ALDH1A1
SCHEMBL16088776 0.75 L3MBTL1 (0.62) POLBSMN1; SMN2MAPK1NPSR1ALDH1A1
SCHEMBL16088780 0.75 TP53 (0.66) POLBSMN1; SMN2MAPK1LMNAHSD17B10
SCHEMBL16088781 0.75 ALDH1A1 (0.61) POLBSMN1; SMN2MAPK1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452170-B2 Compounds and methods for inducing chondrogenesis THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2016-09-27 — — US disclosed
US-20160045514-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2016-02-18 — — US disclosed
US-20140271955-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS THE SCRIPPS RESEARCH INSTITUTE (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160045514-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS COL2A1, BMP4, COL1A1 POLB 3187/4885SMN1; SMN2 3412/4885MAPK1 2174/4885
US-20140271955-A1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS COL2A1, BMP4, COL1A1 POLB 3187/4885SMN1; SMN2 3412/4885MAPK1 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback